What are the latest clinical trials for Pancreatic Cancer in 2026

Latest Clinical Trials for Pancreatic Cancer in 2026

Based on the most current information available, here's what's happening with pancreatic cancer clinical trials heading into 2026:

Trials With Data Expected in 2026

PANOVA-4: Electricity-Based Treatment Study

According to Let's Win Pancreatic Cancer, the PANOVA-4 trial has completed enrollment and is expected to report results in 2026. This study is investigating an innovative electricity-based treatment approach for pancreatic cancer, measuring outcomes like:

• Overall survival (how long patients live)
• Progression-free survival (time before cancer grows)
• Objective response rate (how well tumors shrink)
• Treatment side effects and tolerability

This represents a potentially "much-needed addition to pancreatic cancer treatment," though researchers emphasize more work is needed.

---

Major Treatment Approaches Being Studied

1. KRAS-Targeted Therapies

According to Dr. [removed] O'Reilly's 2024 webinar on novel pancreatic cancer therapies, RMC-6236 is a leading KRAS inhibitor in development:

• Currently in Phase 2/3 trials
• Designed to target ALL major forms of mutant KRAS (the driver of 90% of pancreatic cancers)
• Being tested in patients with metastatic pancreatic cancer who've had prior chemotherapy
• Compared against standard chemotherapy to see if it improves survival

Why this matters: KRAS mutations were once considered "undruggable," but breakthrough drugs are now changing that landscape.

2. Immunotherapy & Vaccine Approaches

Multiple vaccine trials are actively recruiting:

Personalized Neoantigen Vaccines:

• Using [ID removed] technology customized to individual patients' tumors
• Phase 2 trials now open at 80+ locations worldwide
• Early Phase 1 data showed 50% of patients had no cancer recurrence at 18 months after surgery
• Being combined with other immunotherapies for enhanced effect

CD40 Agonists:

• A class of drugs that "activate" the immune system
• Combined with chemotherapy in mid-phase studies showing "nice added cancer shrinkage"
• Moving toward Phase 3 trials

CD73 Inhibitors:

• Target immune suppression in the pancreatic tumor microenvironment
• Early phase studies show promise
• Moving to Phase 3 trials with good tolerability

3. PARP Inhibitors & DNA Repair-Targeted Therapy

For patients with specific genetic mutations (BRCA1, BRCA2, PALB2):

• FDA-approved PARP inhibitors show "striking, durable responses measured in many years"
• Being studied in earlier-stage disease (not just advanced cancer)
• Being combined with immunotherapy in new trials
• High-dose chemotherapy with autologous transplantation (using your own healthy cells) being explored in BRCA-mutated cases

---

Emerging Targets Being Studied

MTAP Deletion

• About 15-20% of pancreatic cancer patients have deletion of the MTAP gene
• New drugs targeting this are in development
• Showing responses even in patients who've had prior chemotherapy

Combination Approaches

The field is moving toward combining multiple treatment strategies:

• KRAS inhibitors + chemotherapy
• KRAS inhibitors + immunotherapy
• PARP inhibitors + immunotherapy
• Chemotherapy + CD40 agonists
• Chemotherapy + CD73 inhibitors

---

How to Find Trials Relevant to YOUR Situation

According to Dr. O'Reilly and the pancreatic cancer community, you should:

1. Get genetic testing at diagnosis - Both germline (hereditary) and somatic (tumor) testing

   • This identifies which trials you might be eligible for
   • "Point of care" testing now available with quick results

2. Use free clinical trial search tools:

   • Massive Bio - Reviews your [ID removed] and recommends suitable trials
   • myTomorrows - Tailors recommendations to your specific needs and geography
   • Cancer Commons - Offers free second opinions
   • PanCAN Trial Finder - Pancreatic cancer-specific search tool

3. Seek second opinions from major academic centers - They typically have the best sense of:

   • What's happening in the field
   • Which trials are most relevant for you
   • Timeline for accessing new treatments

4. Check advocacy organizations:

   • Pancreas Cancer Action Network (PanCAN)
   • National Pancreas Foundation
   • Hirshberg Foundation

---

Important Context for 2026

According to the medical experts cited, the pace of change in pancreatic cancer treatment is accelerating exponentially. What was standard care 6-12 months ago may already be outdated. The field is shifting from "one-size-fits-all" chemotherapy toward personalized medicine based on your tumor's specific genetic profile.

Dr. O'Reilly emphasizes: "What was best six months or a year ago may be old news. The pace of change is increasing exponentially. New tests and treatments are being approved and on the horizon which offer new hope for pancreatic cancer patients."

---

Questions to Ask Your Oncology Team

1. "Has my tumor been molecularly profiled? Can I see the complete report?" (This should include KRAS status, BRCA/PALB2/BRCA2 status, MTAP status, and other mutations)

2. "Based on my specific mutations, which clinical trials am I eligible for?"

3. "Are there trials at academic centers near me that match my tumor profile?"

4. "What's the timeline for accessing newer treatments like KRAS inhibitors or personalized vaccines?"

5. "Should I get a second opinion from a major pancreatic cancer center about trial options?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.

---

Sources Cited:

• Let's Win Pancreatic Cancer - Research Updates 2024-2026
• CancerPatientLab Webinar: "Novel Therapies and New Directions in Pancreas Cancer, 2024" (Dr. [removed] O'Reilly, MD)
• CancerPatientLab Webinar: "Navigating Pancreatic Cancer" (Dr. [removed] Strickler, MD)